SCHEMBL22461745

SCHEMBL22461745

Cc1cnc(C(=O)c2ccnc3[nH]ccc23)c(NS(=O)(=O)c2ccc(C)c(C(F)(F)F)c2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.67
CCR2 P41597 3/20 0.65
CYP2C9 P11712 2/20 0.54
NAMPT P43490 1/20 0.37
NUDT1 P36639 1/20 0.37
TNNI3K Q59H18 3/20 0.36
MAP3K7 O43318 1/20 0.35
MAP4K4 O95819 1/20 0.35
ABL1 P00519 1/20 0.35
RAF1 P04049 1/20 0.35
FES P07332 1/20 0.35
LYN P07948 1/20 0.35
SRC P12931 1/20 0.35
FER P16591 1/20 0.35
EPHA2 P29317 1/20 0.35
EPHB2 P29323 1/20 0.35
FLT3 P36888 1/20 0.35
CSK P41240 1/20 0.35
ABL2 P42684 1/20 0.35
EPHB4 P54760 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1762385 0.92 CYP3A4 (0.79) CYP3A4CCR2CYP2C9JAK1TSHR
SCHEMBL306072 0.92 CYP2C9 (0.65) CYP3A4CCR2CYP2C9CYP2C19
SCHEMBL26066327 0.89 CYP3A4 (0.56) CYP3A4CCR2CYP2C9NUDT1TNNI3K
SCHEMBL25023972 0.89 CYP3A4 (0.64) CYP3A4CCR2CYP2C9NUDT1MAP3K7
SCHEMBL12594265 0.88 CYP3A4 (0.67) CYP3A4CCR2CYP2C9NAMPTTNNI3K
SCHEMBL1188630 0.87 CYP3A4 (0.84) CYP3A4CCR2CYP2C9TNNI3KRAF1
SCHEMBL1762510 0.85 CYP3A4 (0.64) CYP3A4CCR2CYP2C9TNNI3KMAP3K7
SCHEMBL12058592 0.85 CYP3A4 (0.68) CYP3A4CCR2CYP2C9NAMPTTNNI3K
SCHEMBL12594251 0.84 CYP3A4 (0.63) CYP3A4CCR2CYP2C9NUDT1TNNI3K
SCHEMBL306637 0.83 CYP2C9 (0.77) CYP3A4CCR2CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020191240-A1 COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR CHEMOCENTRYX, INC. (US) 2020-09-24 WO disclosed